Incidence of febrile neutropenia with use of docetaxel plus cyclophosphamide (TC) for breast cancer.

被引：0
|
作者：
Patel, Kiran
Diergaarde, Brenda
Brufsky, Adam
Jankowitz, Rachel Catherine
Lembersky, Barry C.
Rastogi, Priya
Huggins-Puhalla, Shannon Leigh
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12073
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel
    Peltekian, Sophie
    Sajwani, Shellyza
    Wang, Xiang
    Kanji, Salmaan
    SUPPORTIVE CARE IN CANCER, 2023, 31 (05)
  • [42] Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel
    Sophie Peltekian
    Shellyza Sajwani
    Xiang Wang
    Salmaan Kanji
    Supportive Care in Cancer, 2023, 31
  • [43] Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
    Adeel, Muhammad
    Asif, Muhammad
    Faisal, Muhammad Naeem
    Chaudary, Muhammad Hasanain
    Malik, Muhammad Sheraz
    Khalid, Muhammad
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 727 - 739
  • [44] Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study
    Rayson, D.
    Lutes, S.
    Sellon, M.
    Colwell, B.
    Dorreen, M.
    Drucker, A.
    Jeyakumar, A.
    Snow, S.
    Younis, T.
    CURRENT ONCOLOGY, 2012, 19 (03) : E216 - E218
  • [45] Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study
    Zhang, Zhisheng
    Li, Huan
    Zhang, Jiacheng
    Ye, Xuan
    Liu, Hongyue
    Zhai, Qing
    Yu, Bo
    Du, Qiong
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5310 - 5315
  • [46] Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer
    Palukuri, Nageswara Reddy
    Yedla, Rajani Priya
    Bala, Stalin Chowdary
    Kuruva, Siva Prasad
    Chennamaneni, Rachana
    Konatam, Meher Lakshmi
    Gundeti, Sadashivudu
    SOUTH ASIAN JOURNAL OF CANCER, 2020, 9 (01) : 4 - +
  • [47] Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres
    Mullard, A. P.
    Misra, V.
    Sumra, P.
    Ali, Z.
    O'Reilly, S. M.
    Malik, Z.
    SUPPORTIVE CARE IN CANCER, 2014, 22 (08) : 2033 - 2037
  • [48] A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study
    Ishikawa, T.
    Shimizu, D.
    Tanabe, M.
    Oba, M. S.
    Sasaki, T.
    Morita, S.
    Kida, K.
    Nawata, S.
    Mogami, M.
    Doi, T.
    Tsugawa, K.
    Ogata, H.
    Kosaka, Y.
    Sengoku, N.
    Saito, Y.
    Suzuki, Y.
    Suto, A.
    Chishima, T.
    Ichikawa, Y.
    Endo, I.
    Tokuda, Y.
    CANCER RESEARCH, 2013, 73
  • [49] Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres
    A. P. Mullard
    V. Misra
    P. Sumra
    Z. Ali
    S. M. O’Reilly
    Z. Malik
    Supportive Care in Cancer, 2014, 22 : 2033 - 2037
  • [50] COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
    Jones, S.
    Chen, L.
    Tangirala, M.
    Asmar, L.
    Airia, P.
    Thompson, M. F.
    VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
12345